BRAF and colorectal carcinoma: It has been reported that targeting BRAF V600E using mono-therapeutic agents, such as vemurafenib (a B-Raf inhibitor, also known as PLX4032) which binds to the ATP-binding site of BRAF V600E to inhibit its activity, shows limited therapeutic response in CRC (Prahallad et al., 2012).